Needham Keeps Their Hold Rating on Lexicon Pharmaceuticals (LXRX)

Needham analyst Joseph Stringer maintained a Hold rating on Lexicon Pharmaceuticals (LXRX – Research Report) today. The company’s shares closed yesterday at $1.70.

Stringer covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Lexicon Pharmaceuticals, and Moderna. According to TipRanks, Stringer has an average return of 0.6% and a 38.48% success rate on recommended stocks.

Lexicon Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $6.33.

Based on Lexicon Pharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $317 thousand and a GAAP net loss of $44.9 million. In comparison, last year the company earned a revenue of $35 thousand and had a GAAP net loss of $24.59 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Lexicon Pharmaceuticals (LXRX) Company Description:

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. It drug candidates include XERMELO, Sotagliflozin, LX2761, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.